Drug intelligence / Profile preview

rutaecarpine

Development stage
Preclinical
Lead developer
Linnet Biopharmaceuticals
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral, Intravenous
01

Overview

Rutaecarpine is a natural pentacyclic indolopyridoquinazolinone alkaloid isolated primarily from the fruit of Evodia rutaecarpa, a traditional Chinese medicinal herb[1][4][5][2]. It is known for diverse pharmacological properties, including vasodilatory, anti-thrombotic, anti-platelet aggregation, anti-inflammatory, analgesic, anti-obesity, and anticancer activities[1][3][5]. Mechanistically, rutaecarpine acts through multiple targets: it is a known inhibitor of cyclooxygenase-2 (COX-2)[5][12][13] and also inhibits COX-1[10]. It can induce degradation of the ABCB1 transporter via upregulation of E3 ubiquitin ligase MARCH8, thereby reversing ABCB1-mediated multidrug resistance (MDR) in cancer cells[1]. Additionally, it activates transient receptor potential vanilloid 1 (TRPV1), leading to increased calcitonin gene-related peptide (CGRP) release and vasodilation, contributing to antihypertensive effects[3]. It shows anti-inflammatory activity by inhibiting NADPH oxidase-dependent production of reactive oxygen species (ROS), inducible nitric oxide synthase (iNOS), and suppression of pro-inflammatory cytokines[3][5]. Rutaecarpine has also demonstrated anti-atherosclerotic, anti-Alzheimer's, antitumor, and anti-obesity properties in multiple preclinical models[1][5].

Other names
rutaecarpineRutacarpineRHETINERutaccarpine
02

Targets

ABCB1 (P-glycoprotein)CD20 (B-lymphocyte antigen CD20)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IL-6 (Interleukin 6)TYK2 (Tyrosine kinase 2)KCNH2 (Voltage-gated potassium channel subfamily H member 2)NOS2 (Nitric Oxide Synthase 2)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)NOX4 (NADPH oxidase 4)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on rutaecarpine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rutaecarpine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call